Detection of Biofilm Disassembly Through a Dispersion Assay
JoVE Encyclopedia of Experiments
Immunology
0 views • 2:49 min • July 8th, 2025
Begin with a multi-well plate containing a bacterial biofilm — bacteria encapsulated within the protective extracellular polymeric substance or EPS.
Aspirate the medium to remove non-adherent bacteria and wash.
Treat bio-film-containing wells with either buffer alone, buffer with glucose, buffer with bile salts, or buffer with glucose and bile salts.
Buffer and glucose treatments support the release of bacterial enzymes that degrade the biofilm's EPS.
This results in the disassembly of the biofilm, releasing the bacteria.
While bile salts and a combination of bile salts and glucose treatments mimic stress conditions and retain bacteria within the protective EPS.
Transfer the supernatant from each well to a fresh multi-well plate.
Spot diluted supernatants on agar plates and incubate.
Enumerate bacterial colonies and determine the bacterial dispersion for each treatment.
A higher dispersion with buffer and glucose treatments compared to bile salts treatments indicates the disassembly of the biofilm.
Record the OD600 values from the overnight biofilm plate on the plate reader by setting the control well as blank. Next, aspirate the culture medium using a vacuum line without disturbing the adherent population on the plastic surface. Gently wash the wells twice with 200 microliters of sterile PBS.
After washing with PBS at 130 microliters of the prewarmed PBS, PBS with glucose, PBS with bile salts, and PBS with bile salts and glucose to each of the three wells. Then incubate the plate at 37 degrees Celsius for 30 minutes. After 30 minutes, remove the plate from the incubator. Pipette the supernatant out to a fresh sterile 96-well plate.
Finally, prepare 1 to 10 serial dilutions of the supernatant with PBS in the 96-well plate or in a dilution block. Then use a multichannel pipette to transfer 5 microliters of each dilution on LB agar plates. Incubate the plates at 37 degrees Celsius overnight. The next day, count the number of colonies.
Overview
This study investigates the disassembly of bacterial biofilms using various treatments. The effects of buffer, glucose, and bile salts on biofilm integrity and bacterial dispersion are analyzed.
Key Study Components
Area of Science
- Microbiology
- Biofilm Research
- Bacterial Physiology
Background
- Bacterial biofilms are complex communities protected by extracellular polymeric substances (EPS).
- Understanding biofilm disassembly can aid in developing strategies to combat bacterial infections.
- Different treatments can influence the stability of biofilms and the release of bacteria.
- This study focuses on the role of glucose and bile salts in biofilm dynamics.
Purpose of Study
- To evaluate the effects of various treatments on the disassembly of bacterial biofilms.
- To determine how glucose and bile salts affect bacterial dispersion.
- To assess the viability of bacteria post-treatment.
Methods Used
- Multi-well plate assays with bacterial biofilms.
- Treatment with buffer, glucose, bile salts, and combinations thereof.
- Enumeration of bacterial colonies on agar plates after incubation.
- Measurement of optical density (OD 600) to assess biofilm growth.
Main Results
- Buffer and glucose treatments resulted in higher bacterial dispersion compared to bile salts.
- Bile salts treatments retained bacteria within the EPS.
- Successful disassembly of biofilms was indicated by increased colony counts.
- OD 600 values confirmed the effectiveness of treatments on biofilm integrity.
Conclusions
- Glucose enhances the disassembly of bacterial biofilms.
- Bile salts maintain biofilm structure under stress conditions.
- Understanding these dynamics can inform therapeutic strategies against biofilm-associated infections.
Frequently Asked Questions
Executive Industry Relevance
Biofilm disassembly assays provide a quantitative readout for evaluating compounds that disrupt bacterial protective matrices, a key mechanism in antimicrobial resistance. By measuring bacterial dispersion via colony forming units, the method supports target validation of anti-biofilm agents and informs lead optimization in infectious disease programs. This enables mechanistic de-risking early in discovery by linking treatment conditions to functional biofilm breakdown.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Interrogates therapeutic hypotheses about biofilm-disrupting mechanisms by quantifying bacterial release from EPS.
- Operational Value: Enables functional target validation through dose-response assessment of glucose, bile salts, or test compounds on biofilm integrity.
- Predictive Value: Supports portfolio triage by identifying agents that promote dispersion under physiologically relevant conditions.
Screening & Assay Development
- Assay Readiness: Prepares standardized biofilm models in multi-well plates for high-throughput compound screening.
- Quantitative Output: Generates dispersion metrics via CFU enumeration, enabling hit selection based on bacterial release efficacy.
- Scalability: Supports assay miniaturization and automation readiness for downstream screening campaigns.
Translational & Preclinical Research
- Disease Relevance: Models biofilm dynamics in enteric pathogens, informing translational studies on persistent infections.
- Mechanistic De-risking: Links molecular interventions to biofilm disassembly, reducing ambiguity in target engagement.
- Preclinical Continuity: Provides a bridge from discovery to in vivo efficacy testing by validating anti-biofilm activity in a controlled system.
Pipeline & Workflow Integration
The assay fits within the discovery continuum from target hypothesis testing to lead identification, offering a functional readout that precedes preclinical validation.
- Discovery Biology: Tests mechanistic hypotheses about biofilm regulation by comparing dispersion across treatment conditions.
- Screening: Delivers reproducible, quantitative dispersion data to prioritize compounds that disrupt EPS.
- Analytics: Uses CFU counts and OD600 measurements to compare biofilm integrity and bacterial viability across conditions.
- Translational Research: Aligns with biomarker strategies by confirming functional biofilm breakdown in disease-relevant models.
- Enterprise Reuse: Establishes a reusable platform for evaluating anti-biofilm agents across multiple pathogen strains.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in target validation by reducing mechanistic ambiguity in biofilm-disrupting activity.
- Operational Value: Delivers standardized, scalable workflows with minimal hands-on time and clear endpoints.
- Strategic Value: Improves go/no-go decisions by identifying compounds with genuine biofilm-disrupting potential early.
- Portfolio Impact: Enables risk-adjusted advancement by filtering out false positives that fail to disperse biofilms.
Implementation Considerations
- Requires expertise in microbiological techniques, including sterile handling and biofilm formation.
- Depends on access to plate readers, incubators, and colony counting instrumentation.
- Necessitates standardization of inoculum density, incubation times, and wash steps across wells.
- Must account for variability in EPS composition across bacterial strains when adapting the assay.
- Limited to planktonic release measurement; does not directly assess biofilm architecture or gene expression changes.
Biopharma FAQs
Biofilm Removal Using Carbon Dioxide Aerosols without Nitrogen Purge
Related Videos
0 Views
Characterization of Aquatic Biofilms with Flow Cytometry
Related Videos
0 Views
Assessing Biofilm Dispersal in Murine Wounds
Related Videos
0 Views
Microtiter Dish Biofilm Formation Assay
Related Videos
0 Views
An Analytical Tool-box for Comprehensive Biochemical, Structural and Transcriptome Evaluation of Oral Biofilms Mediated by Mutans Streptococci
Related Videos
0 Views
Assessing Bacterial Biofilm Formation Using a Cationic Dye-Based Assay
Related Videos
0 Views
Microscopic Assessment of Enzyme-Mediated Inhibition of Biofilm Formation
Related Videos
0 Views
A Peg Plate Biofilm Assay for Screening Antibacterial Agents
Related Videos
0 Views
A Solid Phase Adherence Assay to Assess Biofilm Formation
Related Videos
0 Views
Anti-virulent Disruption of Pathogenic Biofilms using Engineered Quorum-quenching Lactonases
Related Videos
0 Views
Last updated: 22 August 2026